Showing results (511-520 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
The Lancet. Haematology|September 9, 2023
Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort studyTrine Trab, Joachim Baech, Lasse Hjort Jakobsen, et al.
The Lancet. Haematology|August 12, 2023
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international expertsRory M Shallis, Naval Daver, Jessica K Altman, et al.
The Lancet. Haematology|January 8, 2024
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 studyPau Abrisqueta, Eva González-Barca, Carlos Panizo, et al.
The Lancet. Haematology|December 8, 2023
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trialAmer M Zeidan, Kiyoshi Ando, Odile Rauzy, et al.
The Lancet. Haematology|February 29, 2024
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trialMichel Delforge, Krina Patel, Laurie Eliason, et al.
The Lancet. Haematology|February 26, 2024
Natural history of human platelet antigen 1a-alloimmunised pregnancies: a prospective observational cohort studyThijs W de Vos, Dian Winkelhorst, Leendert Porcelijn, et al.
The Lancet. Haematology|February 1, 2024
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyondValentin Lacombe, Jérome Hadjadj, Sophie Georgin-Lavialle, et al.
The Lancet. Haematology|June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre studyKim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
The Lancet. Haematology|May 26, 2024
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USAMohammad K Khan, Tahseen H Nasti, Joshua Y Qian, et al.
Pageof 73